

### **ASX Announcement**

## Melbourne, 24th October 2013

# **Results of Annual General Meeting**

The Annual General Meeting of CogState Ltd was held yesterday in accordance with the notice of meeting.

In accordance with Listing Rule 3.13.2, we confirm that the items of business set out in the notice of meeting were passed as ordinary resolutions on a show of hands.

As required by Section 251AA(2) of the Corporations Act 2001 the attached document details the statistics in respect of each resolution on the agenda.

### For further information contact:

Rebecca Wilson
Buchan Consulting
+61 3 9866 4722 or 0417 382 391
rwilson@buchanwe.com.au

Brad O'Connor Cogstate Chief Executive Officer +61 3 9664 1300 or 0411 888 347 boconnor@cogstate.com

### **About Cogstate**

Cogstate Ltd (ASX: CGS) is a multi-faceted cognitive assessment and training company, focused on the development and commercialisation of rapid, computerised tests of cognition (brain function). It has three distinct business units:

Clinical Trials: In the clinical drug trial market, Cogstate technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, Cogstate has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Targacept, Otsuka, and Servier.

**Axon Sports:** The mission of Axon Sports is to "protect and train the athletic brain". Axon's focus is to research, develop and deliver cutting edge tools to assess, monitor and improve the athletic brain.

Axon has been developing sport specific training products, initially focussed on American football and baseball, and the resulting technologies have now been launched within a small number of elite US college programs. In addition, the first of Axon's consumer iPad apps was launched in 2012.

In the area of sports related concussion, Cogstate's technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. That technology is now marketed to consumers as Axon Sports. Current users of Cogstate/Axon Sports in Australia include the AFL and NRL, whilst in the USA elite programs such as the NBA, WNBA, NHL as well as college programs such as University of Notre Dame, University of Michigan and University of Connecticut all use the Axon Sports system.

Healthcare: In the primary care or general practice setting, the Cogstate's COGNIGRAM™ assesses cognition in patients and the reports generated on the basis of this assessment can allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer's disease. Cogstate intends to develop COGNIGRAM™ to monitor changes in cognitive function following concussion or after treatment with drugs or other types of interventions. In June 2012, Cogstate entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote COGNIGRAM™ in Canada.



ANNUAL GENERAL MEETING Wednesday, 23 October, 2013

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

		Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
Resolution		Votes <b>For</b>	Votes <b>Against</b>	Votes Discretionary	Votes <b>Abstain</b>	For	Against	Abstain **
2	ADOPT THE REMUNERATION REPORT (NON-BINDING VOTE)	14,667,097	463,742	107,464	15,300,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3A	RE-ELECTION OF DIRECTOR - MR DAVID SIMPSON	33,471,697	0	107,464	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3B	RE-ELECTION OF DIRECTOR MR RICHARD VAN DEN BROEK	33,471,697	0	107,464	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4A	ISSUE OF OPTIONS TO MR MARTYN MYER	14,714,170	421,669	82,464	15,295,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4B	ISSUE OF OPTIONS TO MR DAVID SIMPSON	14,606,429	529,410	82,464	15,295,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4C	ISSUE OF OPTIONS TO MR RICHARD VAN DEN BROEK	14,606,429	529,410	82,464	15,295,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4D	ISSUE OF OPTIONS TO MR RODOLFO CHAPA	14,606,429	468,742	143,132	15,295,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4E	ISSUE OF OPTIONS TO MR BRADLEY O'CONNOR	14,667,097	468,742	82,464	15,295,564	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
5	APPROVAL OF 10% PLACEMENT FACILITY	32,932,288	463,741	107,464	75,668	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

<sup>\*\* -</sup> Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item